Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization_Chinese Journal of Ocular Fundus Diseases

Authors：

QiHang ,  ChenChangzheng , YizuoHuizi , 周芸芸

Eye Center, Renmin Hospital of Wuhan University, Wuhan 430060, China;

Corresponding author：

ChenChangzheng, Email: whuchenchzh@163.com

Keywords：

Choroid/physiopathology; Choroidal neovascularization/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies; monoclonal/therapeutic use; Tomography; optical coherence

DOI：

10.3760/cma.j.issn.1005-1015.2015.01.009

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To study changes in choroidal thickness(CT) with intravitreal injections of ranibizumab treatment. Methods This is a prospective, uncontrolled, open-label study. A total of 31 eyes of 31 patients diagnosed with wet age-related macular degeneration (AMD) and 33 eyes of 33 patients diagnosed with choroidal neovascularization (CNV) secondary to pathological myopia (PM) were included in the study. All affected eyes were treated with intravitreal ranibizumab 0.05 ml (10 mg/ml) and followed up monthly until 6 months. Enhanced depth imaging on Cirrus spectral-domain optical coherence tomography was used to measure the CT. The initial CT was compared with the data at 1, 3 and 6 month after treatment, and the correlation between of the decrease of CT at the 6 month and the number of injection times was analyzed. Results In AMD group, the average CT respectively decreased by (9.68±11.02), (12.58±11.04), (13.84±11.67)μm at 1, 3 and 6 month, and the differences were significant(t=4.89, 6.34, 6.60;P < 0.001). In PM group, the average CT respectively decreased by (2.06±10.92), (3.64±8.78), (3.27±7.20)μm at 1, 3 and 6 month. The difference at 1 month was not significant (t=1.08, P=0.287). While after 3 months and 6 months, the differences were significant(t=2.38, 2.61;P=0.024, 0.014). The injection times were not correlated with the CT decreases at 6 month in both groups(r=0.04, 0.30;P=0.815, 0.099). Conclusion Intravitreal injections of ranibizumab can induce choroidal thickness reduction for wet age-related macular degeneration and choroidal neovascularization secondary to pathologic myopia.

Citation： QiHang, ChenChangzheng, YizuoHuizi. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization. Chinese Journal of Ocular Fundus Diseases, 2015, 31(1): 31-35. doi: 10.3760/cma.j.issn.1005-1015.2015.01.009 Copy

1.	Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia[J]. Invest Ophthalmol Vis Sci, 2010, 51(7):3721-3725.
2.	Wood A, Binns A, Margrain T, et al. Retinal and choroidal thickness in early age-related macular degeneration[J].Am J Ophthalmol, 2011, 152(6):1030-1038.
3.	Chung SE, Kang SW, Lee JH, et al. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(5):840-845.
4.	Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration:evidence from clinical trials[J]. Br J Ophthalmol, 2010, 94(1):2-13.
5.	Monés JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia:12-month results[J]. Eye, 2009, 23(6):1275-1280.
6.	Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization:12-month results[J]. Retina, 2010, 30(3):407-412.
7.	Vadalà M, Pece A, Cipolla S, et al.Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study[J].Br J Ophthalmol, 2011, 95(5):657-661.
8.	Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization[J]. Clin Ophthalmol, 2012(6):837-844.
9.	Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration[J]. Lancet, 2012, 379(9827):1728-1738.
10.	Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration:twelve-month results of the DENALI study[J]. Ophthalmology, 2012, 119(5):1001-1010.
11.	CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration:two-year results[J]. Ophthalmology, 2012, 119(7):1388-1398.
12.	Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits[J]. Retina, 2007, 27(9):1260-1266.
13.	Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey[J].Invest Ophthalmol Vis Sci, 2007, 48(6):2814-2823.
14.	Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab[J]. Am J Ophthalmol, 2007, 143(6):995-1002.
15.	Shimomura Y, Hirata A, Ishikawa S, et al. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection[J]. Graefe's Arch Clin Exp Ophthalmol, 2009, 247(8):1089-1094.
16.	Kang HM, Kwon HJ, Yi JH, et al. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injection for typical exudative age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(5):1013-1021.
17.	Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography[J].Am J Ophthalmol, 2008, 146(4):496-500.
18.	Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy[J]. Retina, 2010, 30(1):100-106.
19.	Yamazaki T, Koizumi H, Yamagishi T, et al. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration:12-month results[J]. Ophthalmology, 2012, 119(8):1621-1627.
20.	Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes[J]. Am J Ophthalmol, 2009, 147(5):811-815.
21.	McDonnell EC, Heussen FM, Ruiz-Garcia H, et al. Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age-related macular degeneration[J]. Eur J Ophthalmol, 2014, 24(6):897-903.
22.	Shao L, Xu L, Chen CX, et al. Reproducibility of subfoveal choroidal thickness measurements with enhanced depth imaging by spectral-domain optical coherence tomography[J]. Invest Ophthalmol Vis Sci, 2013, 54(1):230-233.

1. Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia[J]. Invest Ophthalmol Vis Sci, 2010, 51(7):3721-3725.
2. Wood A, Binns A, Margrain T, et al. Retinal and choroidal thickness in early age-related macular degeneration[J].Am J Ophthalmol, 2011, 152(6):1030-1038.
3. Chung SE, Kang SW, Lee JH, et al. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(5):840-845.
4. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration:evidence from clinical trials[J]. Br J Ophthalmol, 2010, 94(1):2-13.
5. Monés JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia:12-month results[J]. Eye, 2009, 23(6):1275-1280.
6. Silva RM, Ruiz-Moreno JM, Rosa P, et al. Intravitreal ranibizumab for myopic choroidal neovascularization:12-month results[J]. Retina, 2010, 30(3):407-412.
7. Vadalà M, Pece A, Cipolla S, et al.Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study[J].Br J Ophthalmol, 2011, 95(5):657-661.
8. Ellabban AA, Tsujikawa A, Ogino K, et al. Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization[J]. Clin Ophthalmol, 2012(6):837-844.
9. Lim LS, Mitchell P, Seddon JM, et al. Age-related macular degeneration[J]. Lancet, 2012, 379(9827):1728-1738.
10. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration:twelve-month results of the DENALI study[J]. Ophthalmology, 2012, 119(5):1001-1010.
11. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration:two-year results[J]. Ophthalmology, 2012, 119(7):1388-1398.
12. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits[J]. Retina, 2007, 27(9):1260-1266.
13. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey[J].Invest Ophthalmol Vis Sci, 2007, 48(6):2814-2823.
14. Peters S, Heiduschka P, Julien S, et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab[J]. Am J Ophthalmol, 2007, 143(6):995-1002.
15. Shimomura Y, Hirata A, Ishikawa S, et al. Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection[J]. Graefe's Arch Clin Exp Ophthalmol, 2009, 247(8):1089-1094.
16. Kang HM, Kwon HJ, Yi JH, et al. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injection for typical exudative age-related macular degeneration[J]. Am J Ophthalmol, 2014, 157(5):1013-1021.
17. Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography[J].Am J Ophthalmol, 2008, 146(4):496-500.
18. Lim SJ, Roh MI, Kwon OW. Intravitreal bevacizumab injection for central serous chorioretinopathy[J]. Retina, 2010, 30(1):100-106.
19. Yamazaki T, Koizumi H, Yamagishi T, et al. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration:12-month results[J]. Ophthalmology, 2012, 119(8):1621-1627.
20. Margolis R, Spaide RF. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes[J]. Am J Ophthalmol, 2009, 147(5):811-815.
21. McDonnell EC, Heussen FM, Ruiz-Garcia H, et al. Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age-related macular degeneration[J]. Eur J Ophthalmol, 2014, 24(6):897-903.
22. Shao L, Xu L, Chen CX, et al. Reproducibility of subfoveal choroidal thickness measurements with enhanced depth imaging by spectral-domain optical coherence tomography[J]. Invest Ophthalmol Vis Sci, 2013, 54(1):230-233.

Chinese Journal of Ocular Fundus Diseases

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content